288847-35-8
Chemical Structure
Combretastatin A1 phosphate
Synonym(s): Oxi4503; CA1P; Combretastatin A1 diphosphate
- CAS No.: 288847-35-8
- Formula:C18H22O12P2
- Molecular Weight:492.31
IUPAC Name: (Z)-3-methoxy-6-(3,4,5-trimethoxystyryl)-1,2-phenylene bis(dihydrogen phosphate)
InChIKey: GSOXMQLWUDQTNT-WAYWQWQTSA-N
SMILES: COC1=C(OP(O)(O)=O)C(OP(O)(O)=O)=C(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)C=C1
Biological Activity: Combretastatin A1 phosphate (Oxi4503) is a potent vascular disruptive agent. Combretastatin A1 phosphate exerts anti-angiogenic effects on tumors. Combretastatin A1 phosphate has the potential for the research of pancreatic neuroendocrine tumors[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Combretastatin A1 phosphate | Combretastatin A1 phosphate (Oxi4503) is a potent vascular disruptive agent. Combretastatin A1 phosphate exerts anti-angiogenic effects on tumors. Combretastatin A1 phosphate has the potential for the research of pancreatic neuroendocrine tumors. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Patterson DM, et al. Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res. 2012 Mar 1;18(5):1415-25. [Content Brief]
- [2]. Nguyen L, et al. Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis. BMC Cancer. 2016 Jul 26;16:533. [Content Brief]
Keywords
